Quality of Life Study in Chronic Diseases: More Needed Than Ever

Laurentius Aswin Pramono

Abstract


Numerous thyroid diseases can impact patients’ lives, one of which is Graves’ ophthalmopathy (GO). Graves’ ophthalmopathy is a progressive thyroid-related disease that causes eye symptoms due to an autoimmune reaction targeting thyrotropin/thyroid stimulating hormone (TSH) receptors in the orbital space. This condition can be easily recognized by the patient, including exophthalmos, pain, swelling, double vision, and impaired vision. Globally, the estimated incidence of GO is 3.3–8 per 100,000 in women and 0.9–1.6 per 100,000 in men with the peak incidence between 30-60 years old. The prevalence of GO is 9 per 100,000, with the prevalence of GO among patients with Graves’ disease reaching 30%.

Anggraini and Nusanti’s study is one of only a few studies in Indonesia that aim to adapt a quality of life questionnaire into Bahasa Indonesia and find out patients’ quality of life afterward, specifically in the thyroid field. The steps for translation, validation, and adaptation of the questionnaire and thus exploring patients' quality of life can be a model for similar studies. Today, our patients not only need assessment for clinical symptoms, signs, laboratory, or radiology results but also need assessment for their well-being and unmet needs which are summarized in the quality of life questionnaires. In the end, optimal quality of care will be the ultimate goal for all chronic disease patients. 


Keywords


Graves Ophthalmopathy; Quality of Life; Questionnaire; Indonesian GO-QoL

References


Li X, Li S, Fan W, et al. Recent advances in graves ophthalmopathy medical therapy: a comprehensive literature review. Int Ophthalmol. 2023;43(4):1437-49.

Uslar V, Becker C, Weyhe D, Tabriz N. Thyroid disease-specific quality of life questionnaires - a systematic review. Endocrinol Diab Metab. 2022;5(5):e357.

Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML. Epidemiology, natural history, risk factors, and prevention of Graves’ orbitopathy. Front Endocrinol (Lausanne). 2020;11:615993.

Bartalena L, Tanda ML. Current concepts regarding Graves’ orbitopathy. J Intern Med. 2022;292(5):692-716.

Smith TJ, Cockerham K, Barretto N, et al. Bridging and validation of the specific Graves ophthalmopathy quality of life questionnaire with health state utility values. Endocr Pract. 2024;30(5):470-5.

Choi YJ, Lim HT, Lee SJ, Lee SY, Yoon JS. Assessing Graves’ ophthalmopathy-specific quality of life in Korean patients. Eye (London, England). 2012;26:544–51.

Villagelin D, Romaldini J, Andrade J, et al. Evaluation of quality of life in the Brazilian Graves’ disease population: focus on mild and moderate Graves’ Orbitopathy patients. Front in Endocrinol. 2019;192.

Lumyongsatien M, Keeratidamkerngsakul B, Pornpanich K, et al. Development and psychometric properties of the Thai Graves’ ophthalmopathy quality of life (GO-QOL) questionnaire. J Patient Rep Outcomes. 2019;4(1):1.

Zeng P, Fan S, Li Z, et al. Evaluation of the Graves’ Orbitopathy-specific quality of life questionnaire in the mainland Chinese population. J Ophthalmol. 2019:7602419.


Full Text: PDF

Refbacks

  • There are currently no refbacks.